For patients currently in compounded GLP-1 programs, the transition would likely involve one of several options: switching to an FDA-approved branded medication (at substantially higher cost), discussing alternative weight management approaches with a licensed provider, or exploring whether 503A patient-specific compounding applies to their individual clinical situation
Guideline Recommendations The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity recommend GLP-1 receptor agonists, including semaglutide 2.4 mg, as first-line pharmacotherapy for adults with BMI 30 or BMI 27 with a weight-related complication
Insurance : Some insurance may cover brand-name Ozempic injections if you meet certain criteria, such as diabetes
In contrast, Ozempic (Semaglutide GLP-1) works as a GLP-1 receptor agonist that mimics natural hormones in the body that regulate blood sugar levels after eating
Compound details
By leveraging the mechanisms that influence appetite, insulin secretion, and digestion, Tirzepatide offers a multi-pronged approach to assist with weight loss
